Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Has Consensus Price Target of $34.79 According to Analysts

Nurix Therapeutics, Inc. (NASDAQ:NRIX) has been assigned a consensus recommendation of “Moderate Buy” from the fifteen research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and thirteen have issued a buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $34.79.

A number of research firms recently weighed in on NRIX. Needham & Company LLC reissued a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a research note on Tuesday, October 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nurix Therapeutics in a research report on Thursday, October 15th. Wall Street Zen upgraded shares of Nurix Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, October 17th. Oppenheimer upped their price objective on Nurix Therapeutics from $28.00 to $32.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 13th. Finally, HC Wainwright boosted their target price on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Friday, October 16th.

Insider Buying and Selling at Nurix Therapeutics

In related news, insider Gwenn Hansen sold 1,452 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $25.00, for a total transaction of $36,300.00. Following the sale, the insider owned 117,227 shares of the company’s stock, valued at approximately $2,930,675. This represents a 1.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julia Gregory sold 22,583 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $23.40, for a total value of $528,442.20. Following the completion of the sale, the director owned 10,750 shares of the company’s stock, valued at $251,550. The trade was a 67.75% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 45,407 shares of company stock valued at $1,083,206 over the last three months. 6.70% of the stock is currently owned by insiders.

Institutional Trading of Nurix Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of NRIX. Sterling Capital Management LLC lifted its position in shares of Nurix Therapeutics by 310.4% during the third quarter. Sterling Capital Management LLC now owns 2,885 shares of the company’s stock valued at $68,000 after buying an additional 2,182 shares during the last quarter. GAMMA Investing LLC increased its holdings in Nurix Therapeutics by 95.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock worth $30,000 after acquiring an additional 620 shares in the last quarter. Farther Finance Advisors LLC increased its position in shares of Nurix Therapeutics by 755.9% during the third quarter. Farther Finance Advisors LLC now owns 4,014 shares of the company’s stock worth $95,000 after purchasing an additional 3,545 shares in the last quarter. Integrated Wealth Concepts LLC purchased a new position in Nurix Therapeutics in the 2nd quarter worth approximately $33,000. Finally, Nykredit A S acquired a new stake in shares of Nurix Therapeutics during the second quarter valued at about $32,000.

Nurix Therapeutics Stock Performance

NRIX stock opened at $26.70 on Friday. Nurix Therapeutics has a 52-week low of $11.37 and a 52-week high of $28.23. The company’s 50 day simple moving average is $24.99 and its 200-day simple moving average is $20.07.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Monday, October 12th. The company reported $4.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $5.33. The firm had revenue of $673.06 million during the quarter, compared to analyst estimates of $24.35 million. On average, research analysts anticipate that Nurix Therapeutics will post 1.14 EPS for the current fiscal year.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that regulate the activity and abundance of proteins involved in cancer and immune-related diseases. Its research is based on targeted protein modulation, including the use of the ubiquitin-proteasome system and E3 ligases to selectively eliminate or modify disease-causing proteins.

The company’s pipeline includes oral targeted protein degraders and other small-molecule therapies. Its investigational programs include NX-5948, a Bruton’s tyrosine kinase (BTK) degrader being studied in B-cell malignancies and autoimmune diseases, and NX-2127, an orally administered BTK degrader designed to combine BTK degradation with immune-system modulation.